Through the molecular engineering of our ActoBiotics® platform
, food-grade microbes (Lactococcus lactis)
, biologically-contained ActoBiotics®
therapeutics allow for expression and secretion of proteins and peptides within the body.
Intrexon through collaboration is pursuing development of biotherapeutics for oral mucositis (OM) and other diseases and conditions of the oral cavity, throat, and esophagus. OM results in the painful inflammation and ulceration of the membranes lining the oral cavity, throat, and esophagus and is among the most frequently reported adverse events associated with cancer therapy affecting up to 500,000 patients annually. At present therapies are primarily palliative alleviating symptoms without addressing the underlying pathology, resulting in a significant unmet medical need.